Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

Insulet shows bullish trends with strong growth, favorable Wall Street ratings, and a 3.2:1 reward-risk ratio. Read more on ...

Corporation shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled ...

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system is worn on the body for approximately three days at a time and allows ...

Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. These figures ...

With shares trading at 8.5 times the midpoint of 2025 sales guidance, William Blair maintains the stock as Outperform. Price Action: PODD stock is down 2.76% at $280.33 at the last check on Friday.

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% from the year-ago period’s figure. The bottom line surpassed the Zacks ...